Octave
Octave Bioscience is a precision medicine company focused on advancing care for neurodegenerative diseases, starting with multiple sclerosis (MS). Their flagship product, the Octave MSDA Test, is the first multi-analyte biomarker blood test specifically developed to measure MS disease activity, providing personalized, data-driven insights to empower patients and healthcare providers in clinical decision-making. The company operates a SaaS and diagnostic business model, delivering clinically relevant biomarker intelligence to transform treatment paradigms and improve patient outcomes. Octave is scaling through clinical evidence generation, strategic medical affairs leadership, and digital marketing to engage healthcare providers and patients, positioning itself as a leader in precision care for MS and other neurodegenerative diseases.
Octave
Octave Bioscience is a precision medicine company focused on advancing care for neurodegenerative diseases, starting with multiple sclerosis (MS). Their flagship product, the Octave MSDA Test, is the first multi-analyte biomarker blood test specifically developed to measure MS disease activity, providing personalized, data-driven insights to empower patients and healthcare providers in clinical decision-making. The company operates a SaaS and diagnostic business model, delivering clinically relevant biomarker intelligence to transform treatment paradigms and improve patient outcomes. Octave is scaling through clinical evidence generation, strategic medical affairs leadership, and digital marketing to engage healthcare providers and patients, positioning itself as a leader in precision care for MS and other neurodegenerative diseases.
TL;DR
Focus: Blood-based multi-protein biomarker assays for multiple sclerosis (MS) and neurodegenerative diseases
Flagship product: Octave MSDA Test — multi-analyte blood test to measure MS disease activity
Business model: SaaS plus diagnostic (laboratory test) delivery
Headcount: 84 employees
Funding (reported): $122,840,000 total disclosed funding
Company Overview
Problem Domain
Measurement of disease activity in multiple sclerosis and related neurodegenerative diseases to support clinical decision-making.
Industry
Biotech / Molecular diagnostics / Precision medicine
Funding Track Record
Public profiles report a Series B on Jul 26, 2023
Public profiles indicate a Series C announced in 2025
Strategic investment announced Oct 11, 2021
Investor Signal
“Syndicate includes strategic and life-science investors such as Merck Global Health Innovation Fund, Northpond Ventures, S32, Casdin Capital, and others”